Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Industry Opposes Expanded Price Cuts under Z2 Rule, Calls for Retention of 60% Pricing Rule for New Injectable, Topical Generics
Top officials of pharmaceutical manufacturing associations objected to expanded reduction rates under the Z2 rule, a special price reduction rule for long-listed drugs, at a meeting of the Central Social Insurance Medical Council’s (Chuikyo) drug pricing subcommittee on December 9.…
To read the full story
Related Article
- JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
- JGA Chief Opposes 50% First Generic Pricing for Non-Oral Drugs with Adoair, Symbicort Generics in Mind
December 11, 2015
- 3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation
December 10, 2015
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…